Answers are grounded in this paper and cite their sources.
Prospective cohort study finds low serum 25 (OH) D linked to increased ovarian and uterine cancer risks.
Background Serum 25 (OH) D levels are associated with various diseases, including cancers, but inconsistencies exist for female-specific malignancies. This study is aimed to explore the real relationship between serum 25 (OH) D levels and incidence rates of female specific cancers in premenopausal women by a large-scale prospective cohort study. Study design We analyzed data from 51,286 UK Biobank participants using Cox regression models to explore associations. Subgroup analyses were based on vitamin D supplementation, alcohol, smoking, BMI, diabetes, sleep, and outdoor exposure. Categorical variables were described by frequencies and compared with chi-squared tests. Results During a median follow-up of 13.8 years, all cancer incidence was 5.1% ( n = 2,614), with ovarian cancer at 0.3% (n = 176), breast cancer at 4.4% ( n = 2,232), and uterine body cancer at 0.5% ( n = 235). Low serum 25 (OH) D (50 nmol/L) was linked to increased risks of ovarian (HR: 1.457, 95% CI: 1.047–2.027) and uterine body cancer (HR: 1.372, 95% CI: 1.023–1.841). Each 10 nmol/L increase in 25 (OH) D reduced ovarian cancer risk (HR: 0.904, 95% CI: 0.835–0.979). Alcohol use and sleep <6 h were risk factors for ovarian and uterine cancer in those with low 25 (OH) D levels. Conclusion Maintaining adequate serum 25 (OH) D levels is essential for overall health, reducing the risk of ovarian cancer, and potentially lowering susceptibility to uterine corpus cancer.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: